Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00274443
Recruitment Status : Completed
First Posted : January 11, 2006
Last Update Posted : November 12, 2019
Information provided by (Responsible Party):

Brief Summary:
This is an open-label dose escalation trial using ABI-007 plus carboplatin.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer (NSCLC) Drug: ABI-007 (Abraxane) and Carboplatin Phase 2

Detailed Description:
This is a multicenter study conducted at study sites in Russia and the Ukraine where various doses of ABI-007 (Abraxane) will be given in combination with carboplatin to patients with non-small cell lung cancer to determine the recommended dose and schedule for this combination therapy for Phase III trials. The primary objective of this study is to obtain preliminary information on the antitumor activity and adverse events of ABI-007 in combination with carboplatin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open -Label, Phase II Trial of Increasing Doses of ABI-007 and Carboplatin in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : March 1, 2005
Actual Primary Completion Date : June 1, 2007
Actual Study Completion Date : June 1, 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ABI-007 and Carboplatin
ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
Drug: ABI-007 (Abraxane) and Carboplatin
ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks

Primary Outcome Measures :
  1. Safety Outcomes: incidence of treatment emergent adverse events. [ Time Frame: Treatment duration ]
  2. Efficacy Outcomes: percentage of patients who achieve an objective confirmed complete or partial overall antitumor response [ Time Frame: Treatment duration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed NSCLC Stage IIIB with pleural effusion or evidence of inoperable local recurrence or metastasis (Stage IV).
  • Male or non-pregnant and non-lactating female, and ≥ 18 years of age. ( )If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (β-hCG) documented within 72 hours of the first administration of study drug. ( )If sexually active, the patient must agree to utilize contraception considered adequate and appropriate by the investigator.
  • No other current active malignancy.
  • Measurable disease
  • Patients must have received no prior therapy for the treatment of metastatic disease.
  • Patient has the following blood counts at baseline:

( ) ANC ≥ 1.5 x 109/L; ( ) platelets ≥ 100 x 109/L; ( ) Hgb ≥ 9 g/dL.

  • Patient has the following blood chemistry levels at baseline:

( ) AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN); ( ) total bilirubin NORMAL; ( ) creatinine ≤ 1.5 mg/dL.

  • Expected survival of > 12 weeks.
  • ECOG performance status 0 or 1.
  • Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities.

Exclusion Criteria:

  • Evidence of active brain metastases, including leptomeningeal involvement. Prior evidence of brain metastasis permitted only if treated and stable off therapy for at least 1 month.
  • The only evidence of metastasis is bone metastases or other nonmeasurable disease.
  • Patient has pre-existing peripheral neuropathy of grade 2, 3, or 4.
  • Patient received radiotherapy in last 4 weeks, except if to a non-target lesion only. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
  • Patient has a clinically significant concurrent illness.
  • Patient is, in the investigator's opinion, unlikely to be able to complete the study through the End of Study visit.
  • Patient has received treatment with any other cytotoxic chemotherapeutic agent or investigational drug within the previous 4 weeks;
  • Patient has a history of allergy or hypersensitivity to the study drug.
  • Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.
  • Patient is enrolled in any other clinical protocol or investigational trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00274443

Layout table for location information
Russian Federation
Study Sites in Russia
St. Petersburg, Saint Petersburg, Russian Federation
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Celgene Identifier: NCT00274443    
Other Study ID Numbers: CA028
First Posted: January 11, 2006    Key Record Dates
Last Update Posted: November 12, 2019
Last Verified: November 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Albumin-Bound Paclitaxel
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action